RESEARCH USE ONLY

#CMT

Monographs tagged “CMT”.

Muscle growthACE-083: a locally acting follistatin-Fc ActRII ligand trapACE-083 is Acceleron's follistatin-Fc fusion protein, engineered to act only in the muscle it is injected into. In phase 2 trials in FSHD and CMT it reliably increased muscle volume but did not improve function, and development was discontinued in 2020.